Ulviprubart - Abcuro
Alternative Names: ABC-008; Anti-KLRG1 antibody - AbcuroLatest Information Update: 28 Jun 2024
At a glance
- Originator Abcuro
- Class Anti-inflammatories; Antibodies; Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; C-type lectin antagonists; Immunologic receptor antagonists; NK cell lectin-like antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Inclusion body myositis
- Phase I/II Large granular lymphocytic leukaemia
- Preclinical Autoimmune disorders; Non-Hodgkin's lymphoma
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for phase-I development in Inclusion body myositis in Australia (SC, Injection)
- 13 Jun 2024 Abcuro plans a phase II/III trial for Inclusion Body Myositis (In adults, In elderly) (SC, Injection) in September 2024 (NCT06450886)
- 17 Aug 2023 Preclinical trials in Non-Hodgkin's lymphoma in USA (Parenteral) prior to August 2023 (Abcuro pipeline, August 2023)